AU2021306736A1 - Low-dose pharmaceutical compositions of GHRH analogs and uses thereof - Google Patents

Low-dose pharmaceutical compositions of GHRH analogs and uses thereof Download PDF

Info

Publication number
AU2021306736A1
AU2021306736A1 AU2021306736A AU2021306736A AU2021306736A1 AU 2021306736 A1 AU2021306736 A1 AU 2021306736A1 AU 2021306736 A AU2021306736 A AU 2021306736A AU 2021306736 A AU2021306736 A AU 2021306736A AU 2021306736 A1 AU2021306736 A1 AU 2021306736A1
Authority
AU
Australia
Prior art keywords
ghrh
hexenoyl
pharmaceutically acceptable
frans
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021306736A
Other languages
English (en)
Inventor
Christian Marsolais
Diane POTVIN
Kirill Shingel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theratechnologies Inc
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of AU2021306736A1 publication Critical patent/AU2021306736A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2021306736A 2020-07-05 2021-06-30 Low-dose pharmaceutical compositions of GHRH analogs and uses thereof Pending AU2021306736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063048167P 2020-07-05 2020-07-05
US63/048,167 2020-07-05
PCT/CA2021/050904 WO2022006657A1 (en) 2020-07-05 2021-06-30 Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Publications (1)

Publication Number Publication Date
AU2021306736A1 true AU2021306736A1 (en) 2023-01-19

Family

ID=79553399

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021306736A Pending AU2021306736A1 (en) 2020-07-05 2021-06-30 Low-dose pharmaceutical compositions of GHRH analogs and uses thereof

Country Status (9)

Country Link
US (1) US20230270865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4175661A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023533498A (cg-RX-API-DMAC7.html)
KR (1) KR20230035600A (cg-RX-API-DMAC7.html)
CN (1) CN115884783A (cg-RX-API-DMAC7.html)
AU (1) AU2021306736A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183299A1 (cg-RX-API-DMAC7.html)
IL (1) IL298991A (cg-RX-API-DMAC7.html)
WO (1) WO2022006657A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
MX2009010675A (es) * 2007-04-04 2009-10-23 Theratechnologies Inc Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.
EP2421548A4 (en) * 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20200297817A1 (en) * 2019-03-22 2020-09-24 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
CA3037757A1 (en) * 2019-03-22 2020-09-22 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
WO2020205498A1 (en) * 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease

Also Published As

Publication number Publication date
KR20230035600A (ko) 2023-03-14
JP2023533498A (ja) 2023-08-03
EP4175661A1 (en) 2023-05-10
US20230270865A1 (en) 2023-08-31
CN115884783A (zh) 2023-03-31
IL298991A (en) 2023-02-01
EP4175661A4 (en) 2024-08-07
WO2022006657A1 (en) 2022-01-13
CA3183299A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
EP2059260B1 (en) Pharmaceutical compositions comprising hGH for oral delivery
EP2316473B1 (en) Use of calcitonin in osteoarthritis
US20120219603A1 (en) Use of Calcitonin for the Treatment of RA
JP2010523501A (ja) Ghrh分子の医薬製剤
EP2961432B1 (en) Formulations of growth hormone releasing factor (grf) molecules with improved stability
US20220378880A1 (en) Pharmaceutical compositions of ghrh analogs and uses thereof
IL158777A (en) Oral preparations containing parathyroid hormone, calcitonin and sending agent and their use in the preparation of medicines
US20230270865A1 (en) Low-dose pharmaceutical compositions of ghrh analogs and uses thereof
CA3037757A1 (en) Pharmaceutical compositions of ghrh analogs and uses thereof
US20200197494A1 (en) Peptide compositions and methods of use
WO1998041222A1 (en) Obesity protein formulations
JP2810730B2 (ja) モチリン製剤
HK1152229B (en) Use of calcitonin in osteoarthritis